Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks
Accordingly, and in line with currently ongoing trials in HFpEF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
The fix: weigh yourself once per week under consistent conditions
R., Wefers J., and Meier J
Body composition was measured using an EchoMRI-100 qNMR body composition analyzer, and mice were sorted into four groups based on body weight and body fat percentage
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man